1246749-71-2Relevant academic research and scientific papers
Discovery of potent and liver-targeted stearoyl-CoA desaturase (SCD) inhibitors in a bispyrrolidine series
Lachance, Nicolas,Gareau, Yves,Guiral, Sebastien,Huang, Zheng,Isabel, Elise,Leclerc, Jean-Philippe,Leger, Serge,Martins, Evelyn,Nadeau, Christian,Oballa, Renata M.,Ouellet, Stephane G.,Powell, David A.,Ramtohul, Yeeman K.,Tranmer, Geoffrey K.,Trinh, Thao,Wang, Hao,Zhang, Lei
scheme or table, p. 980 - 984 (2012/03/26)
Inhibition of stearoyl-CoA desaturase (SCD) activity represents a potential novel mechanism for the treatment of metabolic disorders including obesity and type II diabetes. To circumvent skin and eye adverse events observed in rodents with systemically-distributed SCD inhibitors, our research efforts have been focused on the search for new and structurally diverse liver-targeted SCD inhibitors. This work has led to the discovery of novel, potent and structurally diverse liver-targeted bispyrrolidine SCD inhibitors. These compounds possess suitable cellular activity and pharmacokinetic properties to inhibit liver SCD activity in a mouse pharmacodynamic model.
HETEROCYCLIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE
-
Page/Page column 74-75, (2010/11/03)
Heterocyclic compounds of structural formula I are inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD). The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease; atherosclerosis; obesity; diabetes; neurological disease; Metabolic Syndrome; insulin resistance; cancer, liver steatosis; and non-alcoholic steatohepatitis.
